BH-30643
A mutant-selective OMNI-EGFR™ Inhibitor
We are evaluating a potentially better way to treat EGFR-positive NSCLC. BH-30643 is a mutant-selective OMNI-EGFR™ inhibitor with an aim to provide greater benefit to patients via:
- High potency against common, atypical and compound EGFR mutations, including those induced by treatment with other EGFR inhibitors.
- Low potency against wild-type EGFR to decrease the risk of toxicities associated with wild-type EGFR activity, including skin rash.
- Potency maintained in the presence of concurrent C797S and/or T790M resistance mutations.
BH-30643 has demonstrated a promising PK and safety profile, including good preclinical cardio-safety. The company is actively enrolling the Phase 1/2 SOLARA clinical trial.
The Need for a Mutant-selective OMNI-EGFR™ Inhibitor
The presence of activating EGFR mutations in subjects with non-small cell lung cancer (NSCLC) confers sensitivity to treatment with EGFR inhibitors. Approximately 80% of observed EGFR mutations fall into the category of classical mutations, while the remaining 20% consist of less common exon 20 insertions mutations and other, atypical EGFR mutations.
EGFR inhibitors serve as the standard of care for EGFR-positive NSCLC. However, treatment resistance can arise due to secondary EGFR mutations such as C797S and T790M, which ultimately limit the long-term efficacy of available EGFR inhibitors. Approved EGFR inhibitors are associated with specific toxicities, including a skin rash attributed to the inhibition of wild-type EGFR.
Despite advancements, a significant unmet need remains in the EGFR -mutated NSCLC treatment landscape. Therefore, BlossomHill Therapeutics’ efforts are ongoing to develop a novel macrocyclic EGFR inhibitor that has potential to improve clinical outcomes through addressing EGFR resistance mutations and achieving deeper and more durable responses in the first line.
More information about our clinical trial (NCT06706076) can be found on our Clinical Trials page.
